Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from widespread shortages in the U.

Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster weight loss drug Zepbound was not dragging down sales. Pfizer sales rose 31% to $17.

Eli Lilly has amassed a market value nearing a trillion dollars based on the assumption that demand for its new weight-loss medicine Zepbound will be virtually bottomless. After the company reported disappointing third-quarter results Wednesday morning,